Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Orchestra BioMed Holdings (OBIO) Equity Average (2022 - 2025)

Historic Equity Average for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $22.0 million.

  • Orchestra BioMed Holdings' Equity Average fell 5125.96% to $22.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.0 million, marking a year-over-year decrease of 5125.96%. This contributed to the annual value of $50.5 million for FY2024, which is 1623.53% down from last year.
  • Per Orchestra BioMed Holdings' latest filing, its Equity Average stood at $22.0 million for Q3 2025, which was down 5125.96% from $8.6 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Equity Average high stood at $94.6 million for Q2 2023, and its period low was -$5.7 million during Q3 2022.
  • For the 4-year period, Orchestra BioMed Holdings' Equity Average averaged around $42.5 million, with its median value being $42.4 million (2024).
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Equity Average soared by 206375.56% in 2023, and later plummeted by 8307.03% in 2025.
  • Over the past 4 years, Orchestra BioMed Holdings' Equity Average (Quarter) stood at $23.2 million in 2022, then soared by 217.86% to $73.8 million in 2023, then tumbled by 46.39% to $39.6 million in 2024, then plummeted by 44.39% to $22.0 million in 2025.
  • Its Equity Average was $22.0 million in Q3 2025, compared to $8.6 million in Q2 2025 and $24.9 million in Q1 2025.